|06-09-2003, 07:16 PM||#1|
Join Date: May 2003
Location: Jacksonville, FL
Motor function recovery for chronic paralysis; new pharmaceutical product in the works for this as yet untapped market
Thursday June 5, 11:05 AM
Sirus Pharmaceuticals announces programme for treatment of loss of cerebral and motor function associated with brain injury and stroke ADVERTISEMENT
Cambridge, UK, June 5 /PRNewswire/ -- Sirus Pharmaceuticals Limited announced initiation of a programme of development of SRSS 025 for treatment of loss of motor function resulting from traumatic brain insult due to injury or stroke. The programme is based upon a molecule which has a history of safe use in man which, combined with Sirus' proprietary delivery technologies, could provide a practical means for treatment of patients with this immensely important unmet medical need.
Current therapeutic approaches to treatment of traumatic brain injury primarily rely on treatment immediately after insult and benefits are marginal. Sirus' programme is based upon clinical observations showing significant benefit to patients long after occurrence of the initial damage. Improvement of function has been observed in a significant number of patients with brain trauma, stroke, spinocerebellar ataxia and brain damage due to loss of oxygen by near-drowning experiences. This provides new hope for those suffering coma, traumatic brain injury and ischaemia and other conditions where cerebral and motor function has been retarded.
There are no drugs available which have significant impact upon the longer term symptoms or underlying cause of loss of function due to brain injuries. The market potential is expected to be in excess of US$2 billion.
Tom Saylor, CEO of Sirus, says "SRSS 025 allows Sirus to expand its franchise in treatment of serious conditions of the nervous system. Loss of cerebral and motor function associated with brain injury or stroke is essentially a new therapeutic indication for which there is currently no effective treatment. The nature of the product and the compelling unmet need should allow rapid progression through the development process."
Notes to Editors:
Sirus is an emerging speciality pharmaceutical company developing products for treatment of conditions of the nervous system based upon targeting drugs to the site of disease and chemical modification of drugs to improve their therapeutic effect. Treatment of conditions of the nervous system is typically limited by side effects and poor absorption. By delivering drugs to specifically targeted locations, effective treatment can be achieved with significantly lower dosages and/or reduced side effects. Sirus' technologies also allow greater control over the release of drugs allowing either rapid onset of action, or days or weeks of action as circumstances require.
Sirus is building a rich portfolio of drugs to treat conditions of the nervous system, including neuropathic pain, acute pain, sleep disorders and epilepsy. These products are underpinned by Sirus' three proprietary drug delivery technologies, namely axonal transport, controlled kinetic polymers and sublingual (under the tongue) targeting and delivery systems. Sirus' lead product is for breakthrough cancer pain which is expected to be in Phase III clinical development over the next year. Sirus' targeting and advanced delivery technologies will allow many existing and emerging drugs to be formulated for enhanced therapeutic effect with a reduced side effect profile.
Stroke represents a particularly large market and a serious unmet need, as about 90% of stroke survivors have symptoms such as aphasia (difficulty in communication) or dyskinesia (difficulty in moving). There are no drugs available which relieve these symptoms or which correct the underlying cause.
Sirus is led by a highly experienced Board of Directors. Its Chairman, Dr Andy Richards, was co-founder of Chiroscience and is one of the leading entrepreneurs in British biotechnology. CEO Tom Saylor built an integrated pharmaceutical company in Asia and has many years' experience in the pharmaceutical marketing environment. R&D Director, Dr Fran Crawford, was R&D Director of Ethical Pharmaceuticals and Elan Transdermal, and brings valuable clinical development expertise. The Company's teams of 12 engaged in research in Cambridge and 6 in formulations in Northamptonshire, are complemented by executives with proven marketing and commercialisation experience.